We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-16.16%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.06B
AUM Growth
-$377M
Cap. Flow
-$48.8M
Cap. Flow %
-4.62%
Top 10 Hldgs %
61.75%
Holding
64
New
2
Increased
7
Reduced
31
Closed
8

Top Buys

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$22.9M
2
IRTC icon
iRhythm Holdings
IRTC
+$6.02M
3
SLDB icon
Solid Biosciences
SLDB
+$6.01M
4
IMNM icon
Immunome
IMNM
+$5.12M
5
PODD icon
Insulet
PODD
+$4.75M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$12.5M
2
BSX icon
Boston Scientific
BSX
+$12M
3
SYK icon
Stryker
SYK
+$11M
4
ISRG icon
Intuitive Surgical
ISRG
+$8.84M
5
ARDX icon
Ardelyx
ARDX
+$7.99M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
51
DELISTED
Ventyx Biosciences
VTYX
$1.81M 0.17%
1,569,793
+1,445,615
+1,164% +$2.48M
ATXS
52
DELISTED
Astria Therapeutics
ATXS
$1.44M 0.14%
269,078
-77,200
-22% -$540K
IVVD icon
53
Invivyd
IVVD
$265M
$1.38M 0.13%
2,285,320
-726,934
-24% -$652K
BOLD
54
Boundless Bio
BOLD
$65.1M
$1.1M 0.1%
725,204
-15,000
-2% -$31.1K
KLRS
55
Kalaris Therapeutics
KLRS
$97.6M
$666K 0.06%
82,955
– –
ALLK
56
DELISTED
Allakos
ALLK
$195K 0.02%
856,615
-2,158,482
-72% -$975K
ACIU icon
57
AC Immune
ACIU
$269M
– –
-1,034,299
Closed -$2.79M
ADAP
58
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-715,607
Closed -$385K
ARDX icon
59
Ardelyx
ARDX
$986M
– –
-1,576,259
Closed -$7.99M
HOOK
60
DELISTED
HOOKIPA Pharma
HOOK
– –
-106,376
Closed -$214K
ISRG icon
61
Intuitive Surgical
ISRG
$130B
– –
-16,943
Closed -$8.84M
STXS icon
62
Stereotaxis
STXS
$147M
– –
-1,799,465
Closed -$4.1M
SYK icon
63
Stryker
SYK
$124B
– –
-30,676
Closed -$11M
ACHL
64
DELISTED
Achilles Therapeutics
ACHL
– –
-1,608,089
Closed -$1.83M
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2025 Portfolio in Review

As of Q1 2025, Redmile Group held 64 positions worth $1.06B, down 26% from $1.43B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Redmile Group withdrew a net $48.8M in Q1 2025, closing 8 positions and reducing 31 holdings. Its most notable exit was Stryker, an estimated $11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Redmile Group opened a new position in iRhythm Holdings worth $5.95M.

  • Redmile Group's largest Q1 2025 buy was iRhythm Holdings: 56,844 shares worth $5.95M.
  • Redmile Group added most to Amicus Therapeutics in Q1 2025, an estimated $22.9M increase.
  • Redmile Group's biggest Q1 2025 reduction was Akero Therapeutics, cutting an estimated $12.5M.
  • Redmile Group fully exited Stryker in Q1 2025, selling an estimated $11M.
  • Redmile Group's ten largest holdings make up 62% of its $1.06B portfolio in Q1 2025.
  • Redmile Group opened 2 new positions and closed 8 in Q1 2025.
  • Redmile Group's portfolio value fell 26% quarter-over-quarter to $1.06B.

Based on Redmile Group's 13F filing for Q1 2025, filed 15 May 2025.